

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KELUN-BIOTECH**  
**科伦博泰**

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**

**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6990)**

**VOLUNTARY ANNOUNCEMENT**  
**CORE PRODUCT SKB264 (MK-2870) GRANTED BREAKTHROUGH**  
**THERAPY DESIGNATION FOR FIRST-LINE TREATMENT OF**  
**UNRESECTABLE LOCALLY ADVANCED, RECURRING OR**  
**METASTATIC PD-L1 NEGATIVE TNBC BY THE NATIONAL**  
**MEDICAL PRODUCTS ADMINISTRATION**

The board (the “**Board**”) of directors (“**Directors**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) is pleased to announce that the Company’s core product SKB264 (also known as MK-2870) was recently granted Breakthrough Therapy Designation by the Center for Drug Evaluation of the National Medical Products Administration (NMPA) of China for first-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative triple negative breast cancer (TNBC).

This is the fourth Breakthrough Therapy Designation for SKB264 (MK-2870) granted by the NMPA. Previously, SKB264 (MK-2870) was granted Breakthrough Therapy Designation for locally advanced or metastatic TNBC in July 2022, for EGFR-mutant locally advanced or metastatic non-small cell lung cancer (NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy in January 2023, and for locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer in patients who have previously received at least two lines of systematic chemotherapy in June 2023.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize SKB264 (MK-2870) in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan).

## **RISK WARNING**

**SKB264 (MK-2870) MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.**

By order of the Board  
**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**LIU Gexin**  
*Chairman of the Board and Non-executive Director*

Hong Kong, March 13, 2024

*As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.*